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Introduction
Estrogens and androgens have a crucial role in the prolifera-
tion and progression of breast cancer [1]. Estrogens are
potent mitogens that mediate its proliferative action through
the induction of cyclin D1, the major regulator of entry into
the G1 stage of the cell cycle, and promote the secretion of
positive or negative paracrine growth signals by breast
stroma cells, stimulating epithelial cells to proliferate [2,3].
Androgens might indirectly enhance breast cancer progres-
sion, because they are transformed into estrogens by the
P450 cytochrome aromatase complex [4].
The biological effects of estrogens are mediated by four
different estrogen receptor pathways: (1) classical ligand-
dependent [5], (2) ligand-independent [6], (3) DNA-
binding-independent [7], and (4) cell surface non-genomic
signalling [8]. The first three pathways are mediated by
two structurally related, but distinct, estrogen receptors
(ERs): ER-α and ER-β. The expression patterns of these
two receptors suggest that the genes encoding ER-α and
ER-β are differentially expressed in various tissues. ER-α
expression seems to predominate in the female reproduc-
tive organs, whereas ER-β expression predominates in
non-reproductive organs and the male reproductive tract
[9]. Both receptors have distinct cellular distributions, reg-
ulate separate sets of genes, and can oppose each
other’s actions on some genes; these differences suggest
that the two receptors could have different effects [1].
Most human breast cancers express ER-α, and this
expression is generally considered a manifestation of their
hormonal dependence. In breast cancer, the interruption
AR = androgen receptor; BBD = benign breast disease; CIS = in situ carcinoma; DAX = dosage-sensitive sex reversal, adrenal hypoplasia critical
region, on chromosome X; ER = estrogen receptor; NDS = normal donkey serum; TBS = Tris-buffered saline.
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Abstract
Background: So far there have been no reports on the
expression pattern of DAX-1 (dosage-sensitive sex reversal,
adrenal hypoplasia critical region, on chromosome X, gene 1)
in human breast cells and its relationship to the estrogen
receptors, ER-α and ER-β, and the androgen receptor (AR).
Methods: In this study we evaluated, by immunohistochemistry
and Western blot analysis, the presence and distribution of
DAX-1 in benign breast disease (BBD), in situ carcinoma
(CIS), and ductal and lobular breast carcinomas.
Results: In BBD and breast carcinomas, DAX-1 was present in
both the nuclei and the cytoplasm of epithelial cells, although in
infiltrative carcinomas the percentage of nuclear immuno-
reaction was higher than in CIS. An important relation was
observed between DAX-1 and AR expression and between this
orphan receptor and nodal status.
Conclusion: DAX-1 might modify the AR and ER-β intracellular
location, and because a direct positive relation between the
expression of these three receptors was found it could be
assumed that the presence of DAX-1 in neoplastic cells might
indicate a possible failure of endocrine therapies.
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of ER-α function is an effective therapeutic strategy [10].
Treatment with antiestrogens (tamoxifen) is now the first-
line therapy for metastatic disease, and also adjuvant
therapy after mastectomy. Despite the initial benefits of
tamoxifen, most patients eventually relapse with tumors
that are not only tamoxifen-resistant but are also stimu-
lated by this agent [11]. Although some reports have
shown that the expression of ER-β protein decreases in
neoplastic breast cells, suggesting that ER-β could be an
inhibitor of tumorigenesis [1,12], other studies have sug-
gested that ER-β expression is maintained during breast
cancer progression [3,13,14]. The function of ER-β in
breast pathobiology is therefore unclear, partly because
most studies have focused on its mRNA levels rather than
on the protein [15].
The functional status of androgen receptor (AR) might be
related to the pathogenesis and biological behavior of
female breast cancer [16]. The tissues that express the
lowest levels of AR are the adult breast, the colon, the
lung, and the adrenal gland [17], and a low expression of
AR has also been shown in breast tumors [18]. The mole-
cular mechanism for AR expression loss in breast cancer
is attributed to the active loss of an allele of the gene
encoding AR; this loss might be crucial in predicting and
influencing the response of breast cancer to endocrine
therapy [16]. In addition, the loss of expression or function
of this receptor is related to the activity of regulator pro-
teins such as DAX-1 (dosage-sensitive sex reversal,
adrenal hypoplasia critical region, on chromosome X,
gene 1), an unusual orphan member of the nuclear
hormone receptor superfamily whose expression pattern is
restricted to those tissues directly involved in steroid
hormone production and reproductive function [19]. DAX-
1 functions as a global negative regulator of steroid
hormone production by repressing the expression of multi-
ple genes involved in the steroidogenic pathway [20]. The
function of DAX-1 in females is unknown [21], and its role
in breast cancer has not yet been studied.
The aim of this study was to elucidate the expression
pattern of DAX-1, ER-α, ER-β, and AR in different types of
breast carcinoma by immunohistochemical techniques
and Western blot analysis, to improve our knowledge of
the influence of these receptors in the development and
progression of breast cancer and their possible influence
in endocrine therapies.
Materials and methods
Materials
Breast samples used in this study were obtained by total
or partial mastectomy and included a total of 67 cases: 14
cases of in situ carcinoma (CIS), 24 of infiltrative ductal
carcinoma, 15 of infiltrative lobular carcinoma, and 14 of
benign proliferative diseases including ductal and lobular
hyperplasia, apocrine metaplasia, fibroadenoma, and fibro-
cystic changes. Benign proliferative diseases and CIS
were observed in perimenopausal women (average ± SEM
age 45.81 ± 13.46 years), whereas infiltrative and invasive
tumors belonged to postmenopausal women of higher
average age (59.93 ± 14.89 years). All infiltrative tumor
samples were classified by the TNM system [22]. After
surgery, the hormonal status of each invasive carcinoma-
tous lesion was evaluated, and antiestrogen treatment
(tamoxifen) was applied in the positive cases for its cognate
receptors. Removal of tissues and the study of archive
samples were performed with the consent of the patients’
relatives and permission of the Ethics Committee of the
Príncipe de Asturias Hospital, Alcalá de Henares, Spain.
Each specimen was divided into two approximately equal
portions: one was processed for immunohistochemistry
(fixed with 10% formalin and embedded in paraffin), and
the other was frozen in liquid nitrogen and maintained at
–80°C for Western blot analysis.
Immunohistochemistry
Sections 5 µm thick were processed by using the avidin–
biotin–peroxidase complex (ABC) method. After the
removal of paraffin, sections were hydrated and incubated
for 20 min in 0.3% H2O2 to inhibit endogenous peroxidase
activity; to retrieve the antigen the sections were incu-
bated with 0.1 M citrate buffer (pH 6) for 30 seconds in a
conventional pressure cooker [23]. After being rinsed in
Tris-buffered saline (TBS), the slides were incubated with
3% normal donkey serum (NDS) in TBS for 30 min to
prevent non-specific binding of the first antibody. The sec-
tions were then incubated with mouse monoclonal anti-
ER-α (Novocastra Laboratories Ltd, UK) (1: 60 dilution),
rabbit polyclonal anti-ER-β (Chemicon, Temecula, CA,
USA) (1: 500 dilution), rabbit polyclonal anti-AR (Novocas-
tra) (1: 50 dilution), and rabbit polyclonal anti-DAX-1
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) (1: 20
dilution) primary antibodies, each diluted in TBS contain-
ing 0.3% NDS. Sections were incubated overnight with
primary antibodies: at 37°C for ER-α, ER-β, and DAX-1,
and at 20°C for AR.
The sections were then washed in TBS and incubated for
1 hour with either pig anti-rabbit (for ER-β, AR, and DAX-1)
or rabbit anti-mouse (for ER-α) biotinylated immunoglobu-
lins (Dako, Barcelona, Spain), diluted 1:400 in TBS plus
0.3% NDS. After being washed in TBS, the sections were
incubated with avidin–biotin–peroxidase complex (Dako)
for 1 hour and developed with 3,3′-diaminobenzidine
(DAB), using the glucose oxidase–DAB–nickel intensifica-
tion method [24]. Sections were then dehydrated and
mounted in DePex (Probus, Badalona, Spain).
To assess the specificity of the immunoreaction, negative
and positive controls were used. For negative controls,
adjacent sections of each pathology (benign proliferative
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diseases, and ductal and lobular carcinomas) were incu-
bated with preimmune serum depending on the first anti-
body (mouse serum [for ER-α] and rabbit serum [for ER-β,
AR, and DAX-1]), or using the antibody preabsorbed with
an excess of purified antigens, or omitting the primary anti-
body. As positive controls, sections of rat ovary for ER-α,
human testes for ER-β, and human prostate for the AR
and DAX-1 were processed with the same antibody.
Immunoblotting
For Western blot analysis, tissues were homogenized in
extraction buffer (10 mM Tris-HCl, pH 7.6, 10 mM KCl,
1 mM 1,4-dithiothreitol, and 0.2 M EDTA, pH 8) in addition
to a cocktail of protease inhibitors (1 mM phenylmethane-
sulfonyl fluoride, 10 µg/ml leupeptine, and 1 µg/ml aproti-
nine) and phosphatase inhibitors (200 µg/ml sodium
fluoride and 50 µg/ml sodium orthovanadate) in the pres-
ence of 0.5% Triton X-100 and 0.1% SDS. Homogenates
were centrifuged for 10 min at 10,000 rpm at 4°C. Super-
natants were mixed with an equivalent volume of SDS
buffer (10% SDS in Tris/HCl, pH 8, containing 50% glyc-
erol, 0.1 mM 2-mercaptoethanol, and 0.1% bromophenol
blue). The mixture was then denatured for 4 min at 96°C,
and 70 µg aliquots of protein were subjected to SDS–
polyacrylamide-gel electrophoresis (SDS–PAGE; 9%
polyacrylamide). After SDS–PAGE, proteins were trans-
ferred to nitrocellulose membranes (0.2 µm pore size) in
transfer buffer (25 mM Tris-HCl, 192 mM glycine, 0.1%
SDS, and 20% methanol) for 4 hours at 250 mA constant
current. In brief, the blots for ERs were blocked in 5%
Blotto (Santa Cruz) for 50 min; the sheets for AR and
DAX-1 were blocked in 5% Blotto in addition to 1% NDS
for 30 min. After being blocked, blots were incubated
overnight with primary antibodies diluted 1: 400 (ER-α),
1: 4000 (ER-β), or 1: 200 (AR and DAX-1) in 1: 9 blocking
solution at room temperature (for ER-α, ER-β, and AR) or
at 37°C (for DAX-1).
After extensive washing with TBS/Tween 20, the mem-
branes were incubated with the following peroxidase-con-
jugated secondary antibodies, diluted in 1: 9 blocking
solution: goat anti-mouse for ER-α, or goat anti-rabbit for
ER-β and DAX-1 (Chemicon) at 1: 4000. For AR the
sheets were incubated with the pig anti-rabbit biotinylated
immunoglobulins (Dako) at 1: 2000 and afterwards an
extensive wash with streptavidin–peroxidase (Zymed Lab-
oratories Inc, South San Francisco, CA, USA) at 1: 8000
dilution in the same 1: 9 blocking solution. Finally, the
membranes were developed with an enhanced chemilumi-
nescence kit, in accordance with the procedure described
by the manufacturer (Amersham, Little Chalfont, Bucking-
hamshire, UK).
Statistical analysis
The possible correlation between the principal parameters
recorded in the 39 cases that showed infiltrative carcino-
mas (patient age, axillary lymph node status, disease-free
duration, and DAX-1, ER-α, ER-β, and AR expression),
were evaluated by means of a multivariance analysis of the
principal components. The purpose was to obtain a small
number of linear combinations from the seven variables.
These combinations account for most of the variability in
the data with minimum loss of real data.
The results of principal components analysis were con-
firmed by determination of the correlation of DAX-1
expression and the status of ER-α, ER-β, AR, and several
clinicopathological factors, by using Fisher’s exact test or
the χ2 test (two-tailed).
Correlation of the DAX-1 expression between the different
pathologies studied was calculated with the non-parametric
Spearman correlation coefficient. Statistical analysis was
performed with a StatGraphics computer program.
Results
Western blot analysis
The results of the Western blot analysis are shown in
Fig. 1. For each antibody, only a single band was found at
the corresponding molecular mass: 65 kDa for ER-α,
59 kDa for ER-β, 130 kDa for AR, and 55 kDa for DAX-1.
For ER-α, a similar expression was observed in benign dis-
eases (Fig. 1a) and in CIS (Fig. 1a). Immunoreaction was
more intense in cases presenting infiltrative ductal carci-
noma (Fig. 1a) and infiltrative lobular carcinoma (Fig. 1a).
The band corresponding to ER-β was only observed in
infiltrative lobular carcinoma (Fig. 1b). AR and DAX-1
immunoreactions were observed in benign diseases as
well as in both cancer types (Fig. 1c,d).
Immunohistochemical study of control sections
The immunohistochemical study showed no reaction in
the negative controls incubated with the preimmune
serum, using the antibody preabsorbed with an excess of
purified antigen, or omitting the primary antibody.
Immunostaining of rat ovary, human testis, and human
prostate sections was always positive.
Immunohistochemical study of ER-α
The results obtained by immunohistochemistry are sum-
marized in Table 1.
In benign breast diseases no immunoreaction to ER-α was
observed (Fig. 2a). In CIS, 42.86% of cases showed
nuclear immunoreaction to this receptor (Fig. 2b), and
28.57% presented cytoplasmic reaction. In ductal infiltra-
tive carcinomas (Fig. 2c) the percentage of cases
immunostained in the nuclei increased (62.5%), but those
cases showing cytoplasmic reaction decreased (12.5%).
Infiltrative lobular carcinomas showed nuclear labelling in
60% of cases (Fig. 2d) and cytoplasmic immunoreaction
in 40%.
Immunohistochemical study of ER-β
In benign breast diseases no ER-β expression was found
(Fig. 2e). In CIS, immunostaining was observed in 28.57%
of cases, always in the cytoplasm (Fig. 2f).
In infiltrative ductal carcinoma the percentage of cases
showing nuclear immunoreaction was similar to that
observed in CIS. However, the percentage of cases
showing cytoplasmic labelling (Fig. 2g) was increased
(37.5%). In infiltrative lobular carcinoma (Fig. 2h) the per-
centage of cases showing cytoplasmic immunoreaction
was even higher (60%).
Immunohistochemical study of AR
In the benign diseases no nuclear immunoreaction was
observed (Fig. 2i), although cytoplasmic immunoreaction
was observed in a small proportion of cases (21.4%). In
the remaining pathologies only a few cases showed
nuclear immunostaining, and the number of cases showing
cytoplasmic immunoreaction increased from CIS (28.57%;
Fig. 2j) and infiltrative ductal carcinomas (37.5%; Fig. 2k)
to infiltrative lobular carcinomas (60%; Fig. 2l).
Immunohistochemical study of DAX-1
All pathologies studied, including benign breast diseases,
showed either nuclear or cytoplasmic immunoreaction to
DAX-1 (Fig. 2m–p). The cytoplasmic immunoreaction was
granular and appeared in epithelial cells (Fig. 2n).
The highest percentages of cases showing positive
immunoreaction (in the nucleus or in the cytoplasm) were
found in cancer patients (ductal and lobular). Analysing
the DAX-1 immunoexpression between the different
pathologies studied by using the non-parametric Spear-
man correlation coefficient, we found that the only statisti-
cally significant difference was between benign diseases
and infiltrative lobular carcinomas (P = 0.037, P < 0.05).
Association of DAX-1 expression with ER-α, ER-β, and
AR status and other clinicopathological factors
The results of the principal components analysis, presented
as a two-dimensional component plot (Fig. 3), show the
weights for the principal components analysed (patient age,
axillary lymph node status, disease-free duration, and DAX-
1, ER-α, ER-β, and AR immunoexpression). Each variable is
represented by a point and the reference lines are drawn at
0 for each dimension. A weight close to 0 therefore indi-
cates that the variable contributes little to the component.
All of these variables explain the 53.85% of variability in the
original data. The variables that form an acute angle with
respect to the origin are more correlated. Thus, the most
related variables were AR and DAX-1 expression, although
relations between DAX-1 and nodal status, AR and ER-β,
and between ER-α and both patient age and disease-free
duration were also found. However, no relation was found
between the nodal status and disease-free duration or ER-α
because they were in opposite quadrants.
When the Fisher’s exact or χ2 test was used (Table 2), a
statistically significant difference was observed between
DAX-1 nuclear expression and nodal status (P < 0.05)
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Figure 1
Immunoblots of ER-α (a), ER-β (b), AR (c), and DAX-1 (d) in human
breast. Relative molecular masses are shown at the left. Each blot is
representative of its respective group. For all panels: lane 1, benign
breast disease; lane 2, in situ carcinoma; lane 3, infiltrative ductal
carcinoma; lane 4, infiltrative lobular carcinoma.
and between DAX-1 nuclear and cytoplasmic expression
and AR expression (P < 0.05 and P < 0.001, respectively).
Discussion
In previous reports, ER-α mRNA was detected in 92% of
breast cancers, and ER-β mRNA in 85%; however, after
protein translation, the percentages of cases decreased to
72% and 32%, respectively [25]. This agrees with the
observation of a decrease in ER-β protein expression
when the neoplastic cells begin to proliferate in prolifera-
tive preinvasive mammary tumors [12]. This decreased
level of ER-β protein, associated with cell proliferation,
suggests a protective effect of ER-β against the mitogenic
activity of estrogens in mammary premalignant lesions
[12]. In comparison, the decrease in ER-α protein expres-
sion after translation is lower, suggesting a higher recep-
tivity to estrogens in these preinvasive tumor tissues, and
an increased risk of tumorigenesis [26].
In this study we observed that a high proportion of infiltra-
tive lobular carcinoma cases (60%) showed nuclear
immunostaining for ER-α; the percentage was similar for
infiltrative ductal carcinomas (62.5%). This finding con-
trasts with the absence of immunoreaction in BBD
samples. These results are in agreement with those
observed by Palmieri and colleagues [3], who found low
ER-α expression in fibrocystic disease and high ER-α
expression in invasive ductal cancer.
Our data revealed no correlation between the expression
of ER-α and that of ER-β; thus, all breast carcinomas
analysed gave a negative nuclear reaction to ER-β,
although cytoplasmic expression was found in some
cases. This cytoplasmic location suggests that ER-β is
inactive because of the absence of a ligand, because
these receptors can escape rapidly from the nucleus and
shuttle repeatedly between nucleus and cytoplasm [27]. It
has also been reported that, in endothelial cells, ER-β can
act via the cytoplasm through a novel pathway [28]. This
signal transduction pathway functions through 17β-estra-
diol-activated ER-α and ER-β receptors and induces the
transcriptional activation of Stat-regulated promoters; the
pathway involves an agonist-bound ER-activated phos-
phorylation cascade, resulting in the nuclear transcrip-
tional activation of target transcription factors [28].
Jarvinen and colleagues [13] found that 60% of breast
tumors were ER-β-positive and that this expression was
significantly associated with negative axillary node status
and low grade of malignancy. Mann and colleagues [29]
reported that the expression of ER-β in more than 10% of
cancer cells was associated with better survival. However,
Dotzlaw and colleagues [30] showed that tumors co-
expressing ER-α and ER-β were node-positive and tended
to have higher grade of malignancy. These data suggest
that ER-β might have a role in breast cancer cells and that
this role depends on the presence or absence of ER-α
expression.
The expression of ER-α and ER-β in breast cancer cells is
crucial in determining whether antiestrogen therapy would
be efficient, because some antiestrogenic drugs such as 4-
OH-tamoxifen are more competitive than other estrogenic
substance antagonists of ER-β [31], and do not display
agonist activity when the receptor concentration increases.
ER-β therefore seems to suppress the partial agonist activ-
ity of tamoxifen on ER-α [32], so the response to this treat-
ment will evidently depend on the distribution of these
receptors. In our study, we found that those patients that
showed ER-α expression were usually not the same as
those who showed ER-β expression, and most ER-α+/ER-
β– patients had a poor prognosis and a worse response to
hormonal therapy than ER-α+/ER-β+ patients.
In postmenopausal women, only about 25% of circulating
testosterone arises from that secreted by the ovary. The
remaining 75% comes from circulating precursors derived
from either the adrenal cortex or the ovary [33]. Circulating
levels of these androgenic steroids might be important in
the maintenance of local estrogen synthesis. Adrenal
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Table 1
Numbers of samples showing immunoreaction to ER-α, ER-β, AR, and DAX-1
Infiltrative ductal Infiltrative lobular 
BBD (n = 14) CIS (n = 14) carcinoma (n = 24) carcinoma (n = 15)
Protein N C N C N C N C
ER-α 0 (0) 0 (0) 6 (42.86) 4 (28.57) 15 (62.5) 3 (12.5) 9 (60) 6 (40)
ER-β 0 (0) 0 (0) 0 (0) 4 (28.57) 0 (0) 9 (37.5) 0 (0) 9 (60)
AR 0 (0) 3 (21.4) 1 (7.15) 4 (28.57) 3 (12.5) 9 (37.5) 1 (6.66) 9 (60)
DAX-1 3 (21.42) 5 (35.72) 3 (21.43) 4 (28.57) 9 (37.5) 6 (25) 7 (46.66) 5 (33.33)
Results in parentheses are percentages. AR, androgen receptor; BBD, benign breast diseases; C, cytoplasmic immunoreaction; CIS, in situ
carcinomas; ER, estrogen receptor; N, nuclear immunostaining.
androgens might therefore promote breast cancer,
although higher levels of these hormones might prevent it
[34]. Androgens have two primary effects on mammary
tumor cells: (1) in the absence of estrogens they stimulate
the growth of breast cancer cells by binding to ER-α, and
this effect can be blocked by treatment with antiestrogen;
(2) in the presence of estrogens they act as antiestrogens
to inhibit the stimulation of the growth of breast cancer
cells by estrogen (this effect is exerted through AR and
can be blocked by antiandrogens) [4].
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Figure 2
Expression of estrogen receptors ER-α, ER-β, androgen receptor (AR) and DAX-1 in human breast. (a–d) Immunohistochemistry of ER-α. 
(a) Negative immunoreaction in ductal hyperplasia (magnification ×300). (b) Sample of ductal carcinoma in situ (CIS) showing a strong
immunolabelling of ER-α in the nuclei of neoplastic cells (magnification ×500). (c) A strong nuclear reactivity to ER-α antibody was observed in
samples of infiltrative ductal carcinoma (IDC; magnification ×250). (d) ER-α was observed in the cytoplasm of some cells in infiltrative lobular
carcinoma (ILC; magnification ×300). (e–h) Immunohistochemistry of ER-β. (e) Fibroadenoma was always negative to ER-β (magnification ×300).
(f) Ductal CIS showing an intense cytoplasmic immunoreaction to ER-β (magnification ×400). (g) Positive reaction to ER-β in the cytoplasm of IDC
cells (magnification ×250). (h) ILC showing cytoplasmic reaction to ER-β (magnification ×450). (i–l) Immunohistochemistry of androgen receptor
(AR). (i) Negative reaction to AR antibody in hyperplasia (magnification ×300). In CIS (j) (magnification ×400) and IDC (k) (magnification ×200),
cytoplasmic immunolabelling of AR was observed. (l) ILC showing cytoplasmic immunostaining of AR (magnification ×200). 
(m–p) Immunohistochemistry of DAX-1. An intense cytoplasmic reaction with granular pattern was observed in cases from ductal hyperplasia (m)
(magnification ×200), CIS (n) (magnification ×600), IDC (o) (magnification ×600), and ILC (p) (magnification ×350). BBD, benign breast
diseases.
It has been reported that up to 80% of human breast
tumors are AR-positive and that AR-negative status is cor-
related with the aggressive features of breast cancers
[35], because patients with AR-negative tumors had a sig-
nificantly poorer response rate to hormone therapy than
those with positive tumors [16]. In contrast with these
findings, in this study we observed nuclear immuno-
staining to AR in 7.15% of CIS, 12.5% of infiltrative ductal
carcinomas, and only 6.66% of infiltrative lobular carcino-
mas. However, the percentage of cytoplasmic reaction to
AR in these three pathologies was higher, suggesting that
this receptor forms a multiprotein complex in the cyto-
plasm and, in the presence of ligand, AR becomes tightly
bound in the nucleus [36]. This cytoplasmic location of AR
could be explained by the presence of DAX-1. Recent
studies have suggested that DAX-1 is not exclusively a
nuclear orphan receptor but can be also detected mainly
in the cytoplasm, functioning as a potent corepressor for
estrogen receptors in mammalian cells, presumably by the
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Figure 3
Two-dimensional component plot showing the results of the principal
components analysis obtained from the 39 patients with infiltrative
carcinoma. A close correlation between DAX-1 immunoexpression,
nodal status, and AR expression is observed. Component 1 is on the
x-axis; component 2 is on the y-axis.
Table 2
Association of DAX-1 with various clinicopathological factors and with estrogen receptor-α, estrogen receptor-β and androgen
receptor status
Parameter n Negative Nuclear location P Cytoplasmic location P
Age (years)
≤50 11 5 4 2
>50 28 9 11 0.699 8 0.652
TNM class
T1 19 10 7 2
T2 16 6 6 4
T3 2 1 1 0
T4 2 0 0 0.8486 2 0.216
Nodal status (%)
≤33 26 14 6 6
33–90 10 2 7 1
>90 3 0 1 <0.05 2 0.1439
Histological type
Ductal 24 10 9 5
Lobular 15 4 6 0.699 5 0.4028
Disease-free duration (months)
5–20 3 0 1 2
20–30 10 2 5 3
>30 26 11 9 0.3081 6 0.1713
ER-α
– 10 5 3 2
C 9 2 2 5
N 20 7 10 0.6077 3 0.1649
ER-β
– 23 9 7 7
C 13 5 6 3
N 3 1 2 0.7138 0 0.6766
AR
– 20 12 6 2
C 17 2 7 8
N 2 0 2 <0.05 0 <0.001
AR, androgen receptor; ER, estrogen receptor. C, cytoplasmic immunoreaction; N, nuclear immunostaining.
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direct occupation of the coactivator-binding surface and
the subsequent recruitment of additional corepressor [37].
Moreover, Holter and colleagues [21] demonstrated that
DAX-1 could sequester AR in the cytoplasm, inhibiting its
activation, presumably by both transcriptional and nontrans-
criptional mechanisms, indicating a possible function of
DAX-1 as a cytoplasmic retention factor. We have found
an important relation between AR and DAX-1 expression
in infiltrative carcinomas with the use of principal compo-
nents analysis and Fisher’s exact test, the significance
being higher in the cytoplasmic location frequencies. This
correspondence suggests that this orphan receptor might
be a cytoplasmic retention factor and tethers AR.
DAX-1 is also able to sequester ER-β in the cytoplasm in
an agonist-dependent manner [37]. Like ER-β, DAX-1
seems to be a candidate regulator of AR expression in
tissues such as prostate and ovary [38]; it can be also
assumed that this regulation occurs in breast tissues
because we have observed a statistically significant corre-
lation between ER-β expression and that of AR.
Interestingly, the hormonal steroidogenic pathway seems
to be specifically inhibited by DAX-1 in steroid-producing
cells [21]. The modulation of DAX-1 expression by diverse
bioactive substances and physiological conditions proba-
bly represents an important mechanism for controlling
steroid hormone production [20].
Conclusion
DAX-1 might modify the intracellular location of AR and
ER-β but not that of ER-α. Because we have observed a
direct positive relation between nodal status and DAX-1
expression, it can be assumed that the presence of this
receptor in neoplastic cells might indicate a possible failure
of endocrine therapies; it would therefore be advisable to
study DAX-1 expression in those patients presenting with
breast cancer before hormonal therapy application, and to
develop new therapeutic strategies that can modulate the
action of this receptor to prevent the subsequent resis-
tance that the neoplastic cells acquire.
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